Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)
June 11, 2026 updated by: Arcus Biosciences, Inc.
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
This randomized phase 2 open-label study will evaluate the safety and efficacy of zimberelimab (AB122) monotherapy, domvanalimab (AB154) in combination with zimberelimab, and domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1 positive, metastatic non-small cell lung cancer.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is an open-label phase 2 study in participants with non-small cell lung cancer which will assess the safety, efficacy and tolerability of zimberelimab as monotherapy and in combination with other immunotherapeutics across multiple treatment arms.
Approximately 150 participants will be randomized to 1 of 3 treatment arms: 1) zimberelimab, 2) zimberelimab + domvanalimab (anti-TIGIT antibody), 3) zimberelimab + domvanalimab + etrumadenant (dual adenosine receptor antagonist). Participants that progress on the zimberelimab monotherapy arm may cross-over to receive the third arm combination of zimberelimab + domvanalimab + etrumadenant.
The primary objective of this clinical study is to evaluate the efficacy of each combination therapy by assessing: 1) objective response rate (ORR) of participants with measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) and 2) progression free survival (PFS).
Study Type
Interventional
Enrollment (Actual)
151
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Albury, Australia
- Border Medical Oncology
-
Coffs Harbour, Australia
- Coffs Harbour Health Campus
-
Elizabeth Vale, Australia
- Adelaide Cancer Centre
-
Nowra, Australia
- Shoalhaven Cancer Care Centre
-
-
-
-
-
Montreal, Canada
- McGill University Health Centre (MUHC) - The Montreal Children's Hospital (MCH)
-
-
-
-
-
Hong Kong, Hong Kong
- Hong Kong United Oncology Centre
-
Hong Kong, Hong Kong
- Queen Elizabeth Hospital (Hong Kong)
-
-
-
-
-
Singapore, Singapore
- Curie Oncology
-
-
-
-
-
Busan, South Korea
- Kosin university gospel hospital
-
Cheongju-si, South Korea
- Chungbuk National University Hospital (CBNUH)
-
Hwasun, South Korea
- Chonnam University Hospital
-
Incheon, South Korea
- Gachon University Gil Medical Center
-
Jeonju, South Korea
- Chonbuk National University Hospital
-
Seongnam-si, South Korea
- Seoul National University Bundang Hospital
-
Seoul, South Korea
- Asan Medical Center
-
Seoul, South Korea
- Kangbuk Samsung Hospital
-
Seoul, South Korea
- Korea University Anam Hospital
-
Suwon, South Korea
- St Vincent Hospital of the Catholic University of Korea
-
Uijeongbu-si, South Korea
- Catholic University of Korea, Uijeongbu St. Mary's Hospital
-
-
-
-
-
New Taipei City, Taiwan
- Taipei Medical University - Shuang Ho Hospital
-
Tainan, Taiwan
- National Cheng Kung University Hospital
-
Tainan, Taiwan
- Chi Mei Hospital
-
Taipei, Taiwan
- National Taiwan University Hospital
-
Taipei, Taiwan
- Taipei Medical University Hospital
-
Taoyuan, Taiwan
- Chang Gung Memorial Hospital at Linkou
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama at Birmingham
-
-
California
-
Whittier, California, United States, 90603
- Innovative Clinical Research Institute (ICRI)
-
-
Florida
-
Englewood, Florida, United States, 34223
- Florida Cancer Specialists
-
Gainesville, Florida, United States, 32605
- Florida Cancer Specialists
-
Tallahassee, Florida, United States, 32308
- Florida Cancer Specialists - Panhandle
-
West Palm Beach, Florida, United States, 33401
- Florida Cancer Specialists - East
-
-
Kentucky
-
Lexington, Kentucky, United States, 40503
- Baptist Health Lexington
-
Louisville, Kentucky, United States, 40202
- Norton Cancer Institute
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Ochsner Clinic Foundation
-
-
New Jersey
-
Ridgewood, New Jersey, United States, 07450
- The Valley Hospital - Valley Health System - The Robert and Audrey Luckow Pavilion
-
-
New York
-
Lake Success, New York, United States, 11042
- Clinical Research Alliance
-
Lake Success, New York, United States, 11042
- Northwell Health Cancer Institute
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest Baptist Health
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15224
- Allegheny General Hospital (AGH)-Alleghney Singer Research Institute
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Sarah Cannon Research Institute
-
-
Texas
-
Fort Worth, Texas, United States, 76104
- The Center For Cancer And Blood Disorders (Texas Cancer Care)
-
Houston, Texas, United States, 77339
- Millennium Oncology
-
-
Virginia
-
Blacksburg, Virginia, United States, 24060
- Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
-
Fairfax, Virginia, United States, 22031
- Virginia Cancer Specialists
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female participants; age ≥ 18 years
- Histologically confirmed, treatment naive, metastatic squamous or non-squamous NSCLC with documented high PD-L1 expression, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
- Must have at least 1 measurable lesion per RECIST v1.1
- Adequate organ and marrow function
Exclusion Criteria:
- Use of any live vaccines against infectious diseases within 28 days of first dose of investigational medicinal products (IMPs)
- Any gastrointestinal condition that would preclude the use of oral medications (eg, difficulty swallowing, nausea, vomiting, or malabsorption)
- History of trauma or major surgery within 28 days prior to the first dose of IMP
- Concurrent medical condition requiring the use of supra-physiologic doses of corticosteroids (> 10 mg/day of oral prednisone or equivalent) or immunosuppressive medications
- Positive test results for Hepatitis B surface antigen, Hepatitis C virus antibody with presence of Hepatitis C qualitative RNA or human immunodeficiency virus (HIV-1 and/or HIV-2) antibody at screening
- Any active autoimmune disease or a documented history of autoimmune disease or syndrome that required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for vitiligo or resolved childhood asthma/atopy.
- Prior malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix, breast, or prostate cancer
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Arm 1 (zimberelimab monotherapy)
Participants will receive zimberelimab as an intravenous (IV) infusion.
|
Zimberelimab is a fully human anti-PD-1 monoclonal antibody
Other Names:
|
|
Experimental: Arm 2 (domvanalimab and zimberelimab combination therapy)
Participants will receive domvanalimab IV in combination with zimberelimab IV infusion.
|
Zimberelimab is a fully human anti-PD-1 monoclonal antibody
Other Names:
Domvanalimab is a humanized monoclonal antibody targeting human TIGIT
Other Names:
|
|
Experimental: Arm 3 (domvanalimab, etrumadenant, and zimberelimab combination therapy)
Participants will receive oral etrumadenant in combination with domvanalimab IV and zimberelimab IV infusion
|
Etrumadenant is an A2aR and A2bR antagonist
Other Names:
Zimberelimab is a fully human anti-PD-1 monoclonal antibody
Other Names:
Domvanalimab is a humanized monoclonal antibody targeting human TIGIT
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective response rate (ORR)
Time Frame: From randomization until the first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)
|
ORR as assessed by RECIST v1.1
|
From randomization until the first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)
|
|
Progression-free survival (PFS)
Time Frame: From randomization until the first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)
|
PFS as assessed by RECIST v1.1
|
From randomization until the first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Duration of response (DoR)
Time Frame: From the date of first occurrence of a documented objective response to first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)
|
DoR as assessed by RECIST v1.1
|
From the date of first occurrence of a documented objective response to first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)
|
|
Overall Survival (OS)
Time Frame: From randomization to death from any cause (up to approximately 5 years)
|
OS as assessed at the time of PFS
|
From randomization to death from any cause (up to approximately 5 years)
|
|
Pharmacokinetics of zimberelimab
Time Frame: Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, 60 and 100 days post last dose (in total, an average of 2 years)
|
Serum concentration of zimberelimab as determined by validated assays
|
Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, 60 and 100 days post last dose (in total, an average of 2 years)
|
|
Pharmacokinetics of domvanalimab
Time Frame: Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, 60 and 100 days post last dose (in total, an average of 2 years)
|
Serum concentration of domvanalimab as determined by validated assays
|
Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, 60 and 100 days post last dose (in total, an average of 2 years)
|
|
Pharmacokinetics of etrumadenant
Time Frame: Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, 60 and 100 days post last dose (in total, an average of 2 years)
|
Serum concentration of etrumadenant as determined by validated assays
|
Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, 60 and 100 days post last dose (in total, an average of 2 years)
|
|
Immunogenicity of zimberelimab
Time Frame: Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, and 100 days post last dose (in total, an average of 2 years).
|
Percentage of participants who develop treatment-emergent anti-drug antibodies to zimberelimab
|
Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, and 100 days post last dose (in total, an average of 2 years).
|
|
Immunogenicity of domvanalimab
Time Frame: Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, and 100 days post last dose (in total, an average of 2 years).
|
Percentage of participants who develop treatment-emergent anti-drug antibodies to domvanalimab
|
Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, and 100 days post last dose (in total, an average of 2 years).
|
|
Disease control rate (DCR)
Time Frame: From the date of first occurrence of a documented objective response to first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)
|
DCR as assessed by RECIST v1.1
|
From the date of first occurrence of a documented objective response to first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)
|
|
Number of Participants with Treatment Emergent Adverse Events (TEAEs)
Time Frame: From Screening until up to 90-100 days after the last dose (approximately 5 years)
|
The number and percentage of participants that experience TEAE
|
From Screening until up to 90-100 days after the last dose (approximately 5 years)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Medical Director, Arcus Biosciences, Inc.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 28, 2020
Primary Completion (Actual)
July 9, 2025
Study Completion (Actual)
July 9, 2025
Study Registration Dates
First Submitted
January 23, 2020
First Submitted That Met QC Criteria
February 7, 2020
First Posted (Actual)
February 10, 2020
Study Record Updates
Last Update Posted (Actual)
June 15, 2026
Last Update Submitted That Met QC Criteria
June 11, 2026
Last Verified
August 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ARC-7 (AB154CSP0002)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Arcus will provide access to individual de-identified participant data and related study documents (e.g., protocol, Statistical Analysis Plan [SAP], Clinical Study Report [CSR]) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.
For more information, please visit our website.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.